Dr. Liu Xiao joined our Group on August 15, 2025 as deputy General Manager, mainly responsible for the clinical medicine segment of the company.

Dr. Liu Xiao has over 15 years of experience in new drug clinical development, including 2 years in post-marketing medical affairs and 6 years in preclinical biological evaluation. Before joining our Group , Dr. Liu worked as the Medical Manager of the Clinical Department at Shanghai Hengrui Pharmaceuticals Co., Ltd., mainly responsible for managing medical personnel in the diabetes team and coordinating multiple projects from July 2010 to May 2012. From May 2012 to November 2014, she served as Deputy Clinical Director at Haihe Biopharma Co., Ltd, where she established the clinical department and led teams in formulating clinical development strategies and advancing projects of three innovative drugs（one for hepatitis B and two for oncology）. From November 2014 to July 2025, Dr. Liu successively held roles as Clinical Medical Director and Senior Medical Director at Haisco Pharmaceutical Group Co., Ltd., leading the clinical development and 7 NDA submissions in China of “Ciprofol” (best-in-class innovative drug for anesthetic), as well as the clinical development and 1 NDA submission in China of “Anruikefen” (first-in-class innovative drug for analgesic). She was also involved in regulatory communication and medical support for “Ciprofol” and other products during their registration processes with the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA), and European Medicines Agency (EMA). With extensive clinical experience in anesthesia, critical care, pain management, insomnia, depression, pruritus, coagulation disorders, oncology, autoimmune diseases, antimicrobial therapy, nephropathy, type II diabetes, and hepatitis B, she has led more than 60 Phase I-III registration clinical trials with full-process registration management, and more than 20 Investigator-Initiated Trials (IITs). Her expertise includes end-to-end pipeline development from strategic planning to execution, product lifecycle management, and building cross-disciplinary knowledge networks with industry experts.

Dr. Liu Xiao received her bachelor’s degree in clinical Medicine from Nantong Medical College（currently known as Medical School of Nantong University）in 2003 and her doctorate degree in pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2010.